vorapaxar (Zontivity)

From Aaushi
Jump to navigation Jump to search

Introduction

FDA-approval May 2014[3][4][5]

Indications

* FDA-approved for use in combination with low-dose aspirin or clopidogrel[6]

* do not use alone[7]

Contraindications

Dosage

* each tablet contains 2.5 mg of vorapaxar sulfate, providing 2.08 mg of vorapaxar[7]

Pharmacokinetics

Adverse effects

* no antidote[6][7]

Drug interactions

Mechanism of action

Notes

  • cost: $267 for 30 day supply (2014)

More general terms

References

  1. 1.0 1.1 Tricoci P et al for the TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2011 Nov 13; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22077816 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1109719
  2. 2.0 2.1 Morrow DA et al. for the TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012 Mar 24 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22443427 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1200933
  3. 3.0 3.1 N Engl J Med Journal Watch. Jan 21, 2014 http://www.jwatch.org (subscription required)
    Clarke T FDA advisory panel backs Merck's blood clot-preventing drug. Reuters. Jan 15, 2014 http://www.reuters.com/article/2014/01/15/us-merck-vorapaxar-idUSBREA0E1KV20140115
  4. 4.0 4.1 4.2 4.3 Wood S Medcape. May 8, 2014 FDA Approves PAR-1 Antagonist Zontivity (Vorapaxar) to Reduce MI, Stroke Risk http://www.medscape.com/viewarticle/824886
  5. 5.0 5.1 5.2 FDA News Release: May 8, 2014 FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm396585.htm
  6. 6.0 6.1 6.2 Prescriber's Letter 21(8): 2014 No Detail Document. (subscription needed) http://www.prescribersletter.com
  7. 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 Prescriber's Letter 21(9): 2014 Comparison of Oral Antiplatelets Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300909&pb=PRL (subscription needed) http://www.prescribersletter.com

Database